Ann: Quarterly Appendix 4C and Activities Report, page-216

There’s been some mention about statistical and clinical significance, especially regarding the FSGS study with ten patients. We would be looking for clinical, not statistical significance from the FSGS study.

One doesn’t need to look too far for comparison.

RAC recently released results for their repurposed drug, BISANTRENE.
In mid-June, with a share price of 31.5¢, they released results stating a 40% positive clinical response rate in their malignancy of choice. One patient went into complete remission, and three others achieved partial remission. (Of note, no patients dropped out, but I still can’t find out what happened to the other six....)
There was no mention of statistical significance, the patient sample was too small, but they did claim clinical significance. And in refractory malignancy, any positive cases should be shouted from the rooftops! Who is to know if the one who went into complete remission wasn’t going to do that anyway? Maybe her brand of holy water was better than anyone else’s?
They opened mid-50s, and have progressed up to around $1/share. Peaking at $1.17
Now RAC has 122M SOI, and the market they’re seeking is very large, but BISANTRENE would be used as an adjunct. It would not be stand-alone. Im thinking they’ll be bought out very soon.

Disc: I do not own RAC shares...despite being tipped them around 5¢ last year. I sought the advice of an oncologist-friend, who told me that because BISANTRENE wasn’t a biologic, that it probably wouldn’t fly... My gut said invest, it ticked all my biotech boxes, but I went with a clinical expert in the field... much to my disappointment.

TH tomorrow morning, I reckon.